Akums Zambia order revenue recognition moves to Q1 FY28
Key highlights
- Akums expects Zambia government-order revenue to be recognised in Q1 FY28 after delivery to Lusaka.
- Products are expected to be dispatched in Q4 FY27, but shipping from Haridwar to Lusaka takes roughly 100 to 120 days.
- Akums reported Q2 FY27 consolidated revenue of Rs 1,342 crore, up 31.9% year on year.
- Akums expects its Zambia manufacturing plant to become operational in 2029.
powered by IRIS

Akums Drugs and Pharmaceuticals Limited expects to recognise revenue from its Zambia government order in Q1 FY28, rather than FY27, because products due for dispatch in Q4 FY27 must be delivered to the Zambian government’s Lusaka warehouse after a roughly 100-to-120-day journey from Haridwar.
Know Akums Drugs & Pharmaceuticals inside out
Results, valuation, peers and who's buying, in one view.
When will Akums recognise revenue from the Zambia order?
Akums will recognise the Zambia order as revenue in Q1 FY28 after delivery at the Lusaka warehouse, although it expects to manufacture and dispatch the products in Q4 FY27. Management said purchase orders were received after Zambia’s midyear presidential election, in which the incumbent regime was re-elected, and the company is now supplying against those orders.
The timing differs from much of Akums’ contract development and manufacturing organisation, or CDMO, business. Management said most CDMO contracts are ex works, meaning revenue is booked when goods leave the factory warehouse. The Zambia contract instead requires delivery to the Zambian government’s warehouse in Lusaka, so goods shipped during Q4 FY27 will remain goods in transit in Akums’ financial accounts until delivery in Q1 FY28.
The stated transit time is roughly 100 to 120 days from Haridwar, where Akums expects most products to be manufactured, to Lusaka. That delivery period is the disclosed mechanism preventing the Zambia supplies from increasing reported FY27 sales, even though manufacturing and dispatch are scheduled before the financial year closes.
What is the status of Akums’ Zambia business?
Akums said the first Zambia supply round is a confirmed business with a margin profile management described as slightly better than the company’s CDMO margins. The company has received purchase orders and expects to supply against them in Q4 FY27, leaving manufacturing, dispatch, transit and final warehouse delivery as the remaining execution steps.
Management also said it plans to discuss a further round of supplies with the Government of Zambia after the first delivery is completed. That subsequent supply round is not described as a received purchase order, so it differs from the initial order that Akums said is already intact and under execution.
The Zambia project has a second, longer-term component. Technical discussions for a manufacturing plant in Zambia have been completed, according to management, and Akums expects that plant to become operational in 2029. The proposed site would expand Akums’ manufacturing presence outside India, while the initial government supplies are scheduled to come from Indian facilities.
The contract timing places Zambia alongside other international expansion projects with separate recognition triggers. Akums said its European CDMO project is progressing towards supplies beginning in FY28, but the European dossier still requires regulatory approval. The Zambia order has purchase orders in hand, whereas its revenue trigger is physical delivery to Lusaka.
How does Zambia timing compare with Akums’ current performance?
Akums reported consolidated revenue of Rs 1,342 crore in Q2 FY27, up 31.9% from Rs 1,018 crore in Q2 FY26 and 15.1% from Rs 1,167 crore in Q1 FY27. The Zambia order did not contribute to the reported Q2 FY27 result and, based on the delivery condition, is not expected to be recognised in FY27.
The CDMO segment, which will manufacture the Zambia supplies, reported Q2 FY27 revenue of Rs 1,115 crore, up 38.6% year on year and 15.6% quarter on quarter. Segment earnings before interest, tax, depreciation and amortisation, or EBITDA, were Rs 168 crore, up 99.6% from Rs 84 crore in Q2 FY26 and 2.9% from Rs 163 crore in Q1 FY27.
Akums’ other businesses recorded different growth rates in Q2 FY27. Domestic branded formulations generated Rs 132 crore of revenue, rising 8.2% year on year, while international branded formulations generated Rs 44 crore, rising 95.2%. The active pharmaceutical ingredients, or API, segment reported Rs 29 crore of revenue, down 35.3%, and an EBITDA loss of Rs 5.7 crore, compared with a Rs 14 crore loss in Q2 FY26.
At the consolidated level, EBITDA reached Rs 195 crore in Q2 FY27, compared with Rs 94 crore a year earlier, while profit after tax rose to Rs 115 crore from Rs 43 crore. These figures reflect the existing business mix rather than the Zambia contract, whose first revenue contribution is expected after delivery during Q1 FY28.
Got a follow-up? Ask IRIS
What must happen before Akums books Zambia sales?
Akums must manufacture the ordered products, dispatch them from India in Q4 FY27, complete the roughly 100-to-120-day shipment to Zambia and deliver them to the Lusaka warehouse before it can book related revenue. Management’s explanation makes delivery, rather than production completion or factory dispatch, the key accounting event for the first supply round.
The main disclosed execution consideration is logistics. Products will be recorded as goods in transit after Q4 FY27 dispatch, meaning planned manufacturing activity may occur in FY27 while the related reported sale falls in Q1 FY28. Management did not provide a specific dispatch date, a scheduled Lusaka delivery date or a quarter-by-quarter sales split for the order.
For the longer-term Zambia plant, the disclosed milestone is a 2029 operational target rather than a near-term revenue forecast. Akums said technical discussions are complete, but did not disclose the facility’s capital expenditure, capacity, approvals or revenue-recognition schedule. Those unresolved details are separate from the Indian-made supplies already ordered.
How is Akums funding expansion alongside Zambia execution?
Akums reported cash and cash equivalents of Rs 1,680 crore and free cash flow of Rs 45.5 crore for H1 FY27 after business acquisitions. Management said free cash flow was supported by operating cash flow to EBITDA at a ratio of 69.2% during the first half.
The company said H1 FY27 investment totalled Rs 210 crore, including about Rs 43 crore in the Baddi facility and an Oriflame plant acquisition disclosed at about Rs 56 crore. These investments are separate from the Zambia supply order, but show that Akums is simultaneously funding domestic capacity additions and international projects.
Management said the first phase of the Baddi facility will add oral-solid capacity of more than 6 billion units a year and is expected to be fully operational by Q1 FY28. A second phase is intended to add about 6 billion more tablets, while management did not disclose total capital expenditure for the Baddi project.
Conclusion
Akums has moved the Zambia business from discussion to purchase-order execution, but the reported revenue schedule is governed by delivery terms. Products are expected to be manufactured and dispatched in Q4 FY27, yet the 100-to-120-day Haridwar-to-Lusaka journey means revenue is expected in Q1 FY28 rather than in FY27.
The next disclosed milestones are Q4 FY27 dispatch, delivery to the Lusaka government warehouse and management’s planned discussion of a further supply round after the first delivery. Management also targets Zambia plant operations in 2029, while the European dossier remains subject to regulatory approval that management said could take one or two quarters.


